Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:13:03 EDT Fri 01 Aug 2025
Enter Symbol
or Name
USA
CA



Q:CYDY - CYTODYN INC - https://www.cytodyn.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYDY - Qnot subscribed0.2901-0.0059-2.0793.52241290.297  0.30  0.28750.4945  0.103114:50:44Jul 0115 min RT 2¢

Recent Trades - Last 10 of 129
Time ETExPriceChangeVolume
14:50:44Q0.2901-0.00591,500
14:33:19Q0.29-0.0064,517
14:33:16Q0.29-0.006704
14:29:32Q0.29192-0.00408130
14:19:17Q0.2932-0.00282,500
14:18:26Q0.29-0.00615,855
14:18:25Q0.29-0.00615,855
14:16:17Q0.29-0.006674
14:14:04Q0.2908-0.005215,000
14:14:04Q0.2908-0.00525,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-01 08:30U:CYDYNews ReleaseCytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
2025-06-24 08:30U:CYDYNews ReleaseCytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
2025-05-15 08:30U:CYDYNews ReleaseCytoDyn Releases ESMO Breast Cancer Meeting Poster
2025-05-13 08:30U:CYDYNews ReleaseCytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
2025-05-06 08:30U:CYDYNews ReleaseCytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
2025-04-29 08:30U:CYDYNews ReleaseCytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
2025-03-18 08:30U:CYDYNews ReleaseMarch 2025 Letter to Shareholders
2025-02-24 08:30U:CYDYNews ReleaseCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
2025-02-06 08:30U:CYDYNews ReleaseCytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
2024-12-17 08:30U:CYDYNews ReleaseDecember 2024 Letter to Shareholders
2024-11-25 08:30U:CYDYNews ReleaseCytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
2024-11-04 08:30U:CYDYNews ReleaseCytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
2024-10-30 08:30U:CYDYNews ReleaseCytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
2024-10-08 08:30U:CYDYNews ReleaseCytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
2024-10-07 11:05U:CYDYNews ReleaseCytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
2024-10-04 08:30U:CYDYNews ReleaseCytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
2024-09-24 08:30U:CYDYNews ReleaseCytoDyn Announces Preliminary Findings in Study with SMC Laboratories
2024-09-09 08:30U:CYDYNews ReleaseSeptember 2024 Letter to Shareholders
2024-08-23 08:30U:CYDYNews ReleaseCytoDyn Engages Leading CRO For Phase II Inflammation Trial
2024-08-12 08:30U:CYDYNews ReleaseCytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer